Latest Security News

Hotel Property Investments has confirmed its final ordinary dividend of AUD 0.033 per security for the quarter ending December 31, 2024, with payment scheduled for February 7, 2025. This update finalizes the previously estimated dividend announced in December 2024.

Charter Hall Long WALE REIT reported a resilient half-year performance with near-full occupancy and solid income growth, reaffirming its FY25 earnings and distribution guidance amid strategic portfolio adjustments.

Charter Hall Long WALE REIT reported solid first-half results for FY25, maintaining strong portfolio occupancy and lease terms while executing significant asset sales and strategic acquisitions. The REIT reaffirmed its full-year earnings and distribution guidance, underscoring confidence in its long-term growth strategy.

Charter Hall Long WALE REIT has reversed last year’s heavy losses, reporting a statutory profit of $51.3 million for the half year ended December 2024, while maintaining steady distributions to investors.

Hotel Property Investments (HPI) reported a resilient H1 FY25 with a $1.26 billion portfolio and upgraded its distribution guidance to 19.7 cents per security, despite significant governance changes amid a takeover bid.

Hotel Property Investments (HPI) reported a solid $16.7 million statutory profit for H1 FY25, alongside a 3.2% rise in distributions and a successful debt refinancing that extends maturity and reduces costs.

Hotel Property Investments (HPI) reported a robust half-year profit of A$16.7 million, driven by rising rental income and property valuations, while managing significant takeover defence costs amid Charter Hall Retail REIT and Hostplus bids.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Nick Scali Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the six months ending December 2024, signaling steady shareholder returns.

Lord Resources has uncovered significant gravity anomalies at its Ilgarari Copper Project, revealing promising new drill targets and commencing an earn-in agreement to secure an 80% interest in the sulphide rights.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Shekel Brainweigh Ltd has requested an immediate suspension from ASX quotation as it moves towards removal from the official ASX list, raising questions about the company’s future.